Atossa Therapeutics Stock (NASDAQ:ATOS)


ForecastRevenueOwnershipFinancialsChart

Previous Close

$1.00

52W Range

$0.77 - $2.31

50D Avg

$1.31

200D Avg

$1.39

Market Cap

$129.58M

Avg Vol (3M)

$713.98K

Beta

1.23

Div Yield

-

ATOS Company Profile


Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

12

IPO Date

Nov 08, 2012

Website

ATOS Performance


ATOS Financial Summary


Dec 23Dec 22Dec 21
Revenue---
Operating Income$-31.38M$-27.69M$-20.52M
Net Income$-30.09M$-26.23M$-20.61M
EBITDA$-31.35M$-27.69M$-20.50M
Basic EPS$-0.24$-0.21$-0.18
Diluted EPS$-0.24$-0.21$-0.18

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q2 23Aug 14, 23 | 12:37 PM
Q3 16Nov 14, 16 | 10:18 PM
Q2 16Aug 15, 16 | 7:48 PM

Peer Comparison


TickerCompany
JAGXJaguar Health, Inc.
GOVXGeoVax Labs, Inc.
TNXPTonix Pharmaceuticals Holding Corp.
VXRTVaxart, Inc.
OCGNOcugen, Inc.
ELEVElevation Oncology, Inc.
OCEAOcean Biomedical, Inc.
SONNSonnet BioTherapeutics Holdings, Inc.
NVAXNovavax, Inc.
ENVBEnveric Biosciences, Inc.
INOInovio Pharmaceuticals, Inc.
PALIPalisade Bio, Inc.